{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:45:17Z","timestamp":1779129917878,"version":"3.51.4"},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,17]]},"DOI":"10.18632\/oncotarget.25037","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T10:26:56Z","timestamp":1523874416000},"page":"20928-20940","source":"Crossref","is-referenced-by-count":7,"title":["Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations"],"prefix":"10.18632","volume":"9","author":[{"given":"Richard","family":"Greil","sequence":"first","affiliation":[{"name":"IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center, Paracelsus Medical University, A-5020 Salzburg, Austria"},{"name":"Salzburg Cancer Research Institute, A-5020 Salzburg, Austria"},{"name":"Cancer Cluster Salzburg, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Pleyer","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center, Paracelsus Medical University, A-5020 Salzburg, Austria"},{"name":"Salzburg Cancer Research Institute, A-5020 Salzburg, Austria"},{"name":"Cancer Cluster Salzburg, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Jansko","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Feierabend","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Rettenbacher","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Stiefel","sequence":"additional","affiliation":[{"name":"Ordensklinikum Linz, A-4010 Linz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Rass","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Morre","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Neureiter","sequence":"additional","affiliation":[{"name":"Cancer Cluster Salzburg, A-5020 Salzburg, Austria"},{"name":"Institute of Pathology, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrun","family":"Greil-Ressler","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center, Paracelsus Medical University, A-5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Sokler","year":"2010","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","article-title":"Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group","volume":"18","author":"Maschmeyer","year":"2017","journal-title":"Lancet Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Bentz","year":"2009","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","article-title":"Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group","volume":"26","author":"Jais","year":"2008","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Vose","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"6","first-page":"438","article-title":"Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Bjorkholm","year":"2003","journal-title":"Haematologica"},{"key":"7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a057939","article-title":"Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study","volume":"2","author":"Sundstrom","year":"1991","journal-title":"Ann Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin's disease in the elderly: a population-based study","volume":"119","author":"Taylor","year":"2002","journal-title":"Br J Haematol"},{"key":"9","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"von Tresckow","year":"2013","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Younes","year":"2015","journal-title":"Blood"},{"key":"11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3324\/haematol.2015.134213","article-title":"Impact of post-brentuximab vedotin consolidation on relapsed\/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program","volume":"101","author":"Brice","year":"2016","journal-title":"Haematologica"},{"key":"12","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"Hansmann","year":"2012","journal-title":"J Clin Invest"},{"key":"13","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Shipp","year":"2010","journal-title":"Blood"},{"key":"14","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"de Jong","year":"2016","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ligon","year":"2015","journal-title":"N Engl J Med"},{"key":"16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Savage","year":"2016","journal-title":"Lancet Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"34","author":"Moskowitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12964-016-0155-9","article-title":"Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation","volume":"15","author":"Pleyer","year":"2017","journal-title":"Cell Commun Signal"},{"key":"19","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Koch","year":"2002","journal-title":"Lancet"},{"key":"20","doi-asserted-by":"publisher","first-page":"CD009411","DOI":"10.1002\/14651858.CD009411.pub2","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Skoetz","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.14245","article-title":"Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation","volume":"175","author":"Moskowitz","year":"2016","journal-title":"Br J Haematol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","article-title":"Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma","volume":"19","author":"Hari","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"23","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.1999.17.10.3101","article-title":"High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin\u2019s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation","volume":"17","author":"Goldstone","year":"1999","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2003.04828.x","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease","volume":"124","author":"Yahalom","year":"2004","journal-title":"Br J Haematol"},{"key":"25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3324\/haematol.2011.047670","article-title":"Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy","volume":"97","author":"Kuruvilla","year":"2012","journal-title":"Haematologica"},{"key":"26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.clml.2013.05.007","article-title":"Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed\/refractory Hodgkin lymphoma","volume":"13","author":"Flowers","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"27","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/annonc\/mdu387","article-title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"25","author":"Connors","year":"2014","journal-title":"Ann Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Ruisi","year":"2016","journal-title":"Lancet Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Soiffer","year":"2009","journal-title":"Blood"},{"key":"30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/bjh.12980","article-title":"Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients","volume":"166","author":"Delhem","year":"2014","journal-title":"Br J Haematol"},{"key":"31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","article-title":"Complex immune evasion strategies in classical Hodgkin lymphoma","volume":"5","author":"K\u00fcppers","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Odunsi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"33","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Netto","year":"2012","journal-title":"Cancer Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Okoye","year":"2011","journal-title":"Nature"},{"key":"35","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin Lymphoma with Reduced beta2M\/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status","volume":"4","author":"Hoppe","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Wang","year":"2016","journal-title":"J Hematol Oncol"},{"key":"37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","article-title":"Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells","volume":"184","author":"You","year":"2017","journal-title":"Immunol Lett"},{"key":"38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-15-2001","article-title":"Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNgamma That Induce PD-L1 Expression in Head and Neck Cancer","volume":"76","author":"Ferris","year":"2016","journal-title":"Cancer Res"},{"key":"39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations","volume":"7","author":"Parisi","year":"2017","journal-title":"Cancer Discov"},{"key":"40","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growthand","volume":"20","author":"Shipp","year":"2014","journal-title":"Clin Cancer Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1182\/blood.V124.21.4443.4443","article-title":"Pilot study of ruxolitinib in relapsed or refractory Hodgkin lymphoma and primary mediastinal large B-Cell Lymphoma","volume":"124","author":"Kim","year":"2014","journal-title":"Blood"},{"key":"42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3109\/0284186X.2015.1007212","article-title":"A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma","volume":"54","author":"Provencio","year":"2015","journal-title":"Acta Oncol"},{"key":"43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Rahal","year":"2015","journal-title":"Blood"},{"key":"44","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cellsby nonclassical monocytes in melanoma patients","volume":"112","author":"Speiser","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Sharpe","year":"2010","journal-title":"Immunol Rev"},{"key":"46","doi-asserted-by":"publisher","first-page":"48360","DOI":"10.18632\/oncotarget.10235","article-title":"PD1 blockade enhances cytotoxicity ofexpanded natural killer cells towards myeloma cells","volume":"7","author":"Zheng","year":"2016","journal-title":"Oncotarget"},{"key":"47","doi-asserted-by":"crossref","first-page":"S5536","DOI":"10.1200\/jco.2014.32.15_suppl.5536","article-title":"Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (ots) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC)","volume":"32","author":"Barrett","year":"2014","journal-title":"J Clin Oncol"},{"key":"48","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Orlygsdottir","year":"2011","journal-title":"Nat Genet"},{"key":"49","doi-asserted-by":"publisher","first-page":"djv214","DOI":"10.1093\/jnci\/djv214","article-title":"Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer","volume":"107","author":"Con ti","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"50","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited Mutations in Women With Ovarian Carcinoma","volume":"2","author":"Mannel","year":"2016","journal-title":"JAMA Oncol"},{"key":"51","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jamaoncol.2017.1996","article-title":"Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women","volume":"3","author":"King","year":"2017","journal-title":"JAMA Oncol"},{"key":"52","doi-asserted-by":"publisher","first-page":"47064","DOI":"10.18632\/oncotarget.16791","article-title":"Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer","volume":"8","author":"Calistri","year":"2017","journal-title":"Oncotarget"},{"key":"53","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1002\/cncr.30817","article-title":"Germline genetic variants in men with prostate cancer and one or more additional cancers","volume":"123","author":"Cooney","year":"2017","journal-title":"Cancer"},{"key":"54","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Legius","year":"2015","journal-title":"Lancet Haematol"},{"key":"55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Hacohen","year":"2015","journal-title":"Cell"},{"key":"56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Gajewski","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"57","doi-asserted-by":"publisher","first-page":"R1005","DOI":"10.1186\/bcr1336","article-title":"Mutation analysis of FANCD2, BRIP1\/BACH1, LMO4 and SFN in familial breast cancer","volume":"7","author":"Chenevix-Trench","year":"2005","journal-title":"Breast Cancer Res"},{"key":"58","doi-asserted-by":"publisher","first-page":"e0164370","DOI":"10.1371\/journal.pone.0164370","article-title":"Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes","volume":"11","author":"Aguilar","year":"2016","journal-title":"PLoS One"},{"key":"59","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/jnci\/djn416","article-title":"The SWI\/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia","volume":"100","author":"Cheok","year":"2008","journal-title":"J Natl Cancer Inst"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:35:26Z","timestamp":1589042126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":59,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,4,17]]}},"alternative-id":["25037","29755699"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25037","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]}}}